Drug Discovery & Development Week in Boston, includes five targeted scientific conferences featuring practical strategies to small molecules, antibody therapeutics and oligonucleotide therapeutics from early discovery to the clinic.

Björn Ingemarsson, Ph.D., Chief Scientific Officer, Attana AB will present possibilities to use the Attana systems for kinetic characterization of interactions with immobilized isolated molecules, and with cell surface associated targets. The impact of conjugation and radioactive labelling, of therapeutic antibodies, on antibody-receptor target interaction kinetics, and data on recognition of cell surface glycoconjugates, by means of lectin screening, will be presented.

http://www.drugdisc.com